The company joins Johnson & Johnson and Abbott as top medtech firms that expect an impact in the hundreds of millions of ...

Jon Monson, currently Boston Scientific's senior vice president for investor relations, will replace Brennan beginning June ...

Boston Scientific is doing what most other companies are not: increasing sales guidance for investors despite increasingly ...

Medical device company Boston Scientific (NYSE:BSX) announced in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion ...

After having served as CFO of Boston Scientific since 2014, Brennan will retire from his executive leadership roles at the ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

Q1 2025 Management View CEO Mike Mahoney highlighted strong Q1 performance, with operational sales growth of 22% and organic ...

Though Boston Scientific brought in $4.66 billion in revenue for the first quarter of 2025, up 20.9% year over year, the medical devicemaker is bracing for a potential $200 million hit in the second ...

Boston Scientific stock is up as company officials predict that the ongoing trade war won't hinder double-digit sales growth ...

Brennan’s retirement will break up a long-serving duo at the top of Boston Scientific. Mike Mahoney took up the CEO post in 2012 and still holds the job. On an earnings call Wednesday ...

Compared with $495 million in the year-ago period Boston Scientific CEO Mike Mahoney told investors Wednesday the company expects an impact of about $200 million this year due to the Trump ...